Fennec Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Fennec Pharmaceuticals Inc. has issued its proxy statement for the Annual and Special Meeting of Shareholders scheduled for June 10, 2026, detailing proposals for director elections, auditor appointments, executive compensation votes, and equity plan amendments.
NASDAQ
Fennec Pharmaceuticals is asking shareholders to approve amendments to its equity incentive plan, including increasing the number of shares available for issuance and adding an employee stock purchase program, at the annual meeting on June 3, 2025.
NASDAQ
Fennec Pharmaceuticals will hold its annual shareholder meeting on June 25, 2024, to discuss audited financials, elect directors, appoint auditors, and conduct an advisory vote on executive compensation.